LCG
RCKT icon

Lisanti Capital Growth’s Rocket Pharmaceuticals RCKT Stock Holding History

Lisanti Capital Growth’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-179,705
Closed -$7.96M – 161
2021
Q2 		$7.96M Buy
179,705
+27,287
+18% +$1.19M 0.99% 33
2021
Q1 		$6.76M Buy
152,418
+37,850
+33% +$2.08M 0.87% 50
2020
Q4 		$6.28M Buy
114,568
+31,560
+38% +$1.15M 0.87% 49
2020
Q3 		$1.9M Buy
+83,008
New +$2.05M 0.35% 88
2020
Q2 		– Sell
-38,910
Closed -$543K – 143
2020
Q1 		$543K Buy
38,910
+26,690
+218% +$529K 0.18% 107
2019
Q4 		$278K Buy
+12,220
New +$204K 0.07% 113

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Lisanti Capital Growth's RCKT Position: Q3 2021 in Review

Lisanti Capital Growth sold out of Rocket Pharmaceuticals (RCKT) in Q3 2021, closing a stake of 179,705 shares — an estimated $7.96M sold.

Lisanti Capital Growth first reported a position in RCKT in Q4 2019 and held it in 6 quarters. The position peaked at $7.96M in Q2 2021. 146 funds tracked by Wall St. Rank hold RCKT as of Q3 2021.

  • Lisanti Capital Growth reported no remaining Rocket Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Lisanti Capital Growth sold 179,705 Rocket Pharmaceuticals shares in Q3 2021, an estimated $7.96M.
  • Lisanti Capital Growth first reported a position in Rocket Pharmaceuticals in Q4 2019 and held it in 6 quarters.
  • Lisanti Capital Growth's Rocket Pharmaceuticals position peaked at $7.96M in Q2 2021.
  • 146 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2021.

Based on Lisanti Capital Growth's 13F filing for Q3 2021, filed 3 Nov 2021.